Each year nearly 900,000 US children up to 19 years of age sustain a traumatic brain injury (TBI) requiring hospitalization or emergency treatment.
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
CHICAGO — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved progression-free survival (PFS) versus chemotherapy in previously treated metastatic hormone receptor-positive (HR+)/HER2-low/ultralow breast